Exciting studies involving the molecular regulation of lymphangiogenesis in lymphatic-associated disorders (e.g., wound healing, lymphedema and tumor metastasis) have focused renewed attention on the intrinsic relationship between lymphatic endothelial cells (LECs) and extracellular matrix (ECM) microenvironment. ECM molecules and remodeling events play a key role in regulating lymphangiogenesis, and the "functionality"-relating molecules, especially hyaluronan, integrins, reelin, IL-7, and matrix metalloproteinases, provide the most fundamental and critical prerequisite for LEC growth, migration, tube formation, and survival, although lymphangiogenesis is directly or/and indirectly controlled by VEGF-C/-D/VEGFR-3-Prox-1-, Syk/SLP76-, podoplanin/Ang-2/Nrp-2-, FOXC2-, and other signaling pathways in embryonic and pathological processes. New knowledge regarding the differentiation of initial lymphatics should enable improvements in understanding of a variety of cytokines, chemokines, and other factors. The lymphatic colocalization with histochemical staining by using the novel molecular markers (e.g., LYVE-1), along with subsequent injection technique with ferritin or some tracer, will reveal functional and structural features of newly formed and preexisting lymphatics. Growing recognition of the multiple functions of ECM and LEC molecules for important physiological and pathological events may be helpful in identifying the crucial changes in tissues subjected to lymph circulation and ultimately in the search for rational therapeutic approaches to prevent lymphatic-associated disorders. 83 
INTRODUCTION T
HE LYMPHATIC SYSTEM IS ESSENTIAL for maintenance of normal fluid balance, draining extracellular fluid from the tissues to blood circulation, and providing an exclusive environment in which immune cells can encounter and respond to foreign antigen in peripheral lymphoid tissues as an important immunological defense. Architectural characteristics of the lymphoid tissues are the rich reticular fiber meshworks composed of various molecules in extracellular matrix (ECM). Previous studies have shown an abundant presence of the main ECM components, vitronectin, fibronectin, laminin, type IV collagen, and types I and III collagen in the reticular fibers of spleen, lymph nodes, and tonsil. Recent findings have demonstrated that the interstitial matrix, which occupies the space between the cells, is a very ordered structure of the tissue. Wrapped around the collagen fibers and perhaps attached to them are long molecules of hyaluronan. 1 The ECM plays an important role in fetal and postnatal tissue development, and in the attraction, differentiation,, and retention of monocytes and macrophages that are able to interact with ECM proteins such as laminin and fibronectin via the expression of specific integrin receptors. 2 During embryonic development, specific Department of Anatomy, Biology and Medicine, Oita University Faculty of Medicine, Oita, Japan changes can be distinguished in the ECM composition, 3 which fulfill diverse physiological roles in addition to providing structural support to tissues. The highly developed bioactive substance serves as a medium for cell-cell interactions. Moreover, a variety of processes in lymphatic-associated diseases, (e.g., in the lymphedema, wound healing, and tumor metastasis) in which lymphangiogenesis is a critical factor to initiate and coordinate the sequence of events, are closely related with the molecule composition and functional microenvironment of the ECM. 4 As a rapid progress in the lymphatic field, a better understanding of how ECM molecules influence endothelial cell behaviors will necessitate full insights into how lymphangiogenesis occurs and contributes to local lymph drainage in disordered tissues.
Recently, a novel connection between integrin-mediated adhesion and critical endothelial cell was suggested to function via VEGFR-3, the transmembrane receptor for vascular endothelial growth factor-C (VEGF-C) and VEGF-D. 5 Although VEGF-C/-D are primary lymphatic endothelial cell (LEC) determinants, the behavior of LECs is also mediated by signals from extracellular environment molecules. The particular local ECM environment is assumed to trigger different VEGF receptors, resulting in distinct signaling pathways that promote lymphangiogenesis. The ECM component feature may thus affect lymphocyte migration, adhesion, and proliferation. 6 However, the physiological significance of the regulation of ECM on the differentiation of endothelial cells and on the lymphatic development remains to be determined. In this context, this review will outline the main cytokines, chemokines, and other components relating to ECM and lymphatic growth, and highlight some of the recently published findings in ECM and lymphangiogenesis. The advances in our understanding of the lymphatic biology will lead to new applications in the foreseeable future.
DIFFERENTIATION BETWEEN INITIAL LYMPHATICS AND BLOOD VESSELS
During embryonic development, lymphatics provide a complementary and distinct pathway for maintaining the integrity of tissues. Hypoplasia or dysfunction of the lymphatics can lead to lymphedema, whereas hyperplasia or abnormal growth of these vessels is associated with lymphangiomas and lymphangiosarcomas. Importantly, renewed attention on the mechanisms by which tumor cells enter initial lymphatics has focused on the identification of initial lymphatics and blood capillaries in morphological and molecular biology, which will provide a fundamental prerequisite for the investigation of lymphangiogenesis and its role in lymphatic-related disorders.
The lymphatics act as a one-way transport system, in which initial lymphatics are optimally suited for fluid, protein, particle, and cell uptake from the interstitium. Although initial lymphatics have many properties in common with blood capillaries, they also have distinct morphological features reflecting their specific functions.
Initial lymphatics with blind-ended structures are composed of a single nonfenestrated endothelial layer, showing a wide irregular lumen. The endothelial cells have abundant cell membrane invaginations and cytoplasmic vesicles, as well as obvious overlapping intercellular junctions, although interendothelial tight junctions are usually infrequent. 7 The basement membrane of blood capillaries is developed with encircling pericytes and commonly existed tight junctions. In contrast, initial lymphatics lack mural cells and are characterized by an incomplete or absent basement membrane. The lymphatic endothelial cytoskeleton is directly connected to adjacent ECM by anchoring filaments composed mainly of fine strands of elastic fibers. 8 Interestingly, an elastin microfibril protein that is normally expressed in the elastin-rich tissues, 9 has been found to be selectively and abundantly expressed in LECs.
The transendothelial pathways may be used as a mechanism for the entry of molecules into lymphatics. The study previously demonstrated that lymphatic endothelium is characterized by a high density of anionic sites on cell membranes, particularly along intercellular junctions, 10 which have been suggested to facilitate movement of small solutes and molecules into the lymphatic lumen. The initial lymphatics may thus have the capacity to remove selectively molecules from the interstitium and actively control the composition of lymph and interstitial fluid. In addition, the intercellular open junction is necessary for fluid and proteins into the lymphatics, 7 the entry of which is driven by pressure gradients across the endothelial wall. 11 Changes in components and strains of lymphangiogenic ECM may affect the function of both preexisting and newly formed lymphatics, which may become actively involved in tumor cell chemotaxis, promoting tumor cell invasion and dissemination. 4 If the activated interstitial-lymphatic interface is destroyed and initial lymphatics cannot function, no lymph will be drained from that local region despite the baseline systemic drainage forces, 12 which seems to inhibit tumor cell migration through the lymphatic endothelial walls in the tumor tissues. However, a complex mechanism in the interaction of intratumoral and peritumoral interstitial pressure, upregulation or downregulation of cell adhesion molecules, specific ultrastructure of initial lymphatics will directly force the lymph that carries tumor cells into regional lymph nodes. 13 Recently, the lymphatic colocalization with histochemical staining by using novel molecular markers, along with subsequent intratumoral injection technique with ferritin or some tracer, were widely employed to reveal functional and structural features of newly formed and preexisting lymphatics.
In tumors, once the metastatic cells reach adjacent initial lymphatics, they move along the external surface of the endothelium, led by fine cytoplasmic processes. The cells migrate toward and invade into the lumen either through open junctions or by inducing the opening of closed junctions. 14 Intratumoral interstitial fluid pressure increases as tumors increase in size, 15 and lymph flow is in the direction of the peritumoral lymphatics; as a result, the interstitial fluid volume increases. Anchoring filaments keep the initial lymphatics open, even when the peritumoral interstitial fluid volume and pressure rise. As the interstitium swells, the anchoring filaments not only increase lymphatic lumen diameters but also pull open the intercellular junctions, producing intercellular clefts. Consequently, it is easy for fluid, particles, and cells to pass into the lymphatic lumen. Once the pressure outside the initial lymphatics decreases, these junctions begin to close, preventing retrograde flow into the interstitium. 11 Therefore, a more extensive range of features for initial lymphatics is available to aid in distinguishing blood capillaries (Table 1) (Fig. 1) .
The unique structural and functional differences of initial lymphatics from blood capillaries indicate a significant discrimination at the molecular expression level. 16 The identification of differentially expressed molecules is critical to a better understanding of the mechanisms that modulate lymphatic development and function (Table 2 ). These lymphatic endothelial markers mainly include VEGFR-3, a highly glycosylated and relatively stable fms-like LYMPHATIC ENDOTHELIAL CELLS 85 20 Furthermore, the pace of research into the LEC continues to accelerate with the availability of new molecular markers (e.g., LyP-1 molecular marker of tumor lymphatics, 21 Nrp2 coreceptor of VEGF-C in LECs, integrin␣9␤1 necessary for embryologic development of lymphatics. 22 ).The Tie/ angiopoietin system and neuropilin-2 may also be involved in lymphangiogenesis. In initial lymphatics, constitutive expression of Ang-2 by endothelial cells may account for the characteristic lack of pericytes in these vessels. Initial lymphatics are further distinguished by the specific organization of its intercellular junctions, including the presence of adherens junctions. 23 Several genes encoding proteins that constitute adherens junctions were identified, such as plakophillin 2, H-cadherin, and zona occludens 2. [24] [25] [26] Classification of the differentially expressed genes into functional groups revealed that LECs express remarkably high levels of genes implicated in protein metabolism, sorting, and trafficking, indicating a more active role of lymphatic endothelium in uptake and transport of molecules than previously anticipated. 16 Particularly highly represented were genes encoding proteins that control specificity of vesicle targeting and fusion, such as proteins of the SNARE family, rab GTPases, AAA ATPases, and sec-related proteins, 27, 28 and hematopoietic signaling proteins for regulating blood vascular and lymphatic separation, 29 such as SLP-76 and Syk, indicating pronounced vesicular transport in LECs and separating ability in lymphatic development. 5Ј-nucleotidase (5Ј-Nase) is recognized as a maturation marker (differentiation antigen CD73) for both T and B lymphocytes. 5Ј-Nase enzyme expression depends highly on the physiological state of cells, its activity is much more strong in the LECs than BECs. [30] [31] [32] [33] The ecto-5Ј-Nase may play a role in the interaction of activated cells with either the ECM (especially laminin and fibronectin) and/or with other cells. 34 The application of 5Ј-Nase antibody may provide further information on endothelial cell-ECM interaction. 35 The successful use of lymphatic-specific antibodies to receptors for the isolation and purification of primary LECs represents a major advance in lymphatic biology. The LECs from human cultured cells and dermal cell suspensions were established by immunoselection with antibodies to podoplanin, LYVE-1, and VEGFR3. 16, 36, 37 Two cell lineages were demonstrated to express distinct sets of endothelial markers and respond differently to growth factors and ECM components. These LECs, which are defined as LYVE-1 ϩ /podoplanin ϩ /CD31 ϩ / CD34 Ϫ/low /CD45 Ϫ , were distinct from BECs, defined as LYVE-1 Ϫ /podoplanin Ϫ /CD31 ϩ / CD34 ϩ /CD45 Ϫ . Phenotypic analyses of LECs indicate these cells also express the adherens junction adhesion molecule VE-cadherin and synthesize the leukocyte chemoattractants SLC (CCL21) and MIP-3 (CCL20, Exodus), which, respectively, induce the migration of CCR7-positive and CCR6-positive lymphocytes and dendritic cells to the T-cell areas of lymph nodes. 36, 38, 39 The studies in vitro demonstrated that LECs maintained expression of their characteristic markers in cultured condition. However, the slightly different expression in distinct 40 Lymphatics and blood vessels provide complimentary but distinct pathways for maintaining the integrity of tissues. 22, 41 LECs and BECs appear to be distinct populations that separately serve in lymphangiogenesis and angiogenesis. Lymphangiogenic factors and ECM are two major contributors to a series of LEC functions. The identification of a large number of genes selectively expressed by LECs should facilitate the discovery of hitherto unknown lymphatic markers and provide a basis for the analysis of the molecular mechanisms accounting for the characteristic functions of initial lymphatics. 16 Evidently, improved distinguishing between the two capillary types is crucial for addressing questions regarding the pathology of the lymphatic system. In this respect, clear localization and structure of initial lymphatics, which can also be demonstrated by other immunohistochemical staining antibodies, [42] [43] [44] [45] [46] [47] [48] [49] is necessary for analyzing local environment changes in lymphatic-relating diseased tissues (Fig, 2 ; Table 2 ). It is anticipated that biochemical analysis of primary LECs, particularly the application of cDNA microarray, quantitative real-time RT-PCR, OctoChrome fluorescence in situ hybridization, and genechip technologies for RNA profiling, might further reveal the molecular features that distinguish initial lymphatics from blood capillaries.
ENVIRONMENT FOR LYMPHANGIOGENESIS
Lymphangiogenesis is a term that can be employed to designate the embryonic and postnatal development, and proliferation of new lymphatics by sprouting from veins or/and de novo from lymphangioblasts by extension from the preexisting vessels. 4, 22, [50] [51] [52] [53] [54] [55] The primary lymphatic networks continue to develop into a functional lymphatic system through their budding, sprouting, and remodeling. A wellbalanced process in embryogenesis is important to promote primary lymphatic network as well as adequate initial lymphatics from developing organs, to serve as a functional requirement for lymph drainage in the region. 32 In pathological disorders, lymphangiogenesis which frequently occurs in wound healing, inflammation, lymphedema, and in the establishment and spread of malignant tumors, can induce their own lymph absorption from the preexisting lymphatics in a route that is close to normal lymphangiogenesis. 4 Lymphangiogenesis is thus a central element in a variety of physiological and pathological processes to initiate and coordinate the sequence of events.
Like the process of angiogenesis, 56 lymphangiogenesis might be stimulated by a shift in the balance between lymphangiogenic and antilymphangiogenic factors and depends on specific molecular interactions between the LECs and their surrounding ECM. The endothelial cells need to receive appropriate signals from the changing microenvironment. Several important molecular regulators have been implicated in lymphangiogenesis, including VEGF-C/-D and their receptor VEGFR-3, and Prox1, FOXC2, Tie2/Ang2, podoplanin, LYVE-1, and basic fibroblast growth factor (bFGF via VEGF-C). 57-60 VEGF-C is perhaps the most important of prolymphangiogenic cytokine because of its ability to regulate most of the steps in the lymphangiogenic cascade. In embryogenesis, VEGF-C works as a paracrine signal to establish a concentration gradient toward which the first LECs migrate to form the lymph sac. 61 Study of cell cultures indicated that VEGF-C selectively promoted survival and tube formation of LECs. Interestingly, in the absence of exogenous growth factors, LECs incorporated into collagen type I scaffolds exhibited a significantly higher survival rate than BECs. This difference in response to collagen type I may reflect differences in the type of the ECM that each vessel type is exposed to in its natural environment. 16 In a mouse model of lymphedema, the VEGFR-3-specific mutant form of VEGF-C called VEGF-C156S lacks blood vascular side effects but is sufficient for therapeutic lymphangiogenesis. As VEGF-C156S is a specific lymphatic endothelial growth factor in the skin, it provides an at-tractive molecule for prolymphangiogenic therapy. 62 However, VEGF-C does not enhance LEC migration through a proteolytically sensitive ECM, although in vivo it may do so indirectly through the recruitment of proteolytically active macrophages. 63 Consistent with the previous observations, recent findings indicated that excess VEGF-C does not augment the physiological rate of migration or functionality, and by itself cannot sustain any lasting ef- In the hybridoma metastatic pancreas, the lymphatic vessels containing a cluster of tumor cells show both the expressions of LYVE-1 (e) and podoplanin (f) in the serial sections. Bars ϭ 50 m fects on lymphatic size, density, or organization in regenerating adult skin, although it may enhance early LEC proliferation and cause lymphatic hyperplasia. 64 These studies highlight important differences in the relative roles of VEGF-C versus matrix proteolysis and fluid channel formation in directly inducing LEC migration.
In addition, the first stage of commitment to lymphatic lineage is marked by cells expressing LYVE-1, VEGFR-3, and Prox-1, which start buds, again in a polarized fashion. 40 The homeodomain transcription factor Prox-1, an important LEC fate-determining factor, can induce LEC-specific gene transcription even in BECs. This suggests that the distinct phenotypes of cells in the adult vascular endothelium are plastic and sensitive to transcriptional reprogramming, which might be useful for future therapeutic applications involving endothelial cells. 62 In mice with heterozygous and homozygous disruptions of the T1␣/podoplanin gene, lymph transport was impaired and detectable cutaneous lymphedema occurred in the lower limbs, 65 indicating podoplanin might involved in lymphatic patterning and maturation. FOXC2, which is mutated in the human hereditary disease lymphedema-distichiasis, controls the late stages of lymphatic development. 66 FOXC2 is highly expressed in all developing lymphatics, but in adults the highest expression is observed in the endothelial cells of lymphatic valves. 60, 66, 67 Mice lacking Ang-2 also exhibit major lymphatic defects in the remodeling and function. 68 Taken together, it is quite evident that some key molecular regulators or genes tell LECs to sprout or not. Prox-1, VEGF-C, Syk, and SLP-76 are involved in polarization, budding and sprouting, and separation to form lymph sac, respectively. The developing lymphatics continue their remodeling and maturation through the regulation of podoplanin, Ang-2 and Nrp-2. 40, 57, 68 Indeed, the apparent lymphangiogenic property of many other cytokines and chemokines (e.g., FGF-2) may be mediated by VEGF-C/-D. 36, 69 In lymphatic-associated disorders, moreover, far from these factors will participate in environment-fitting lymphangiogenesis.
It is generally accepted that a preexisting blood vascular bed may be necessary to guide lymphangiogenesis. In embryonic tissues, lymphatics develop shortly after blood vessels and might share a common origin with the latter, 22 although new ECM produced and realigned at appropriate sites, provides the structural integrity and participates in several key events such as cell migration and proliferation for both angiogenesis and lymphangiogenesis.
Histochemical studies demonstrated that the blood vessels often accompany the lymphatic networks, but the structures of both vessels and the ratio of lymphatics to blood vessels varies depending on tissue type and function. 7, 32 It is quite evident that an abundant and neighboring blood supply provides essential nourishment for slender lymphatic walls to have adequate intrinsic contractility and ability to regenerate rapidly when required, processes essential for maintaining fluid balance. 51 Lack of accompanying lymphatic growth would result in increasing tissue edema. Spatio-temporal studies showed that new blood vessels were followed by lymphatics and that the lymphatics grew alongside new veins. 70 In transgenic mice, VEGF-A promoted wound-associated lymphatic formation through VEGFR-2 signaling. The growth of newly formed lymphatics into the wound granulation tissue occurred 1 week later than the sprouting of blood vessels. 71 Recently, an animal experiment of the tumor transfected by human lung cancer demonstrated that angiogenesis has always preceded lymphangiogenesis. 72 The preexisting lymphatics have been supposed to have an important role in guiding the lymphatic growth, however, the experiments in vitro suggested that LECs have the ability to proliferate, migrate, and invade to form a new vessel in the absence of a preexisting lymphatic matrix. 36, 66 These observations and others have led to the belief that a preexisting blood vascular bed may be necessary to guide lymphangiogenesis. 69 Nevertheless, the morphological, spatial, and temporal aspects of lymphangiogenesis remain poorly understood. The lymphatic and blood vascular systems might be coordinately regulated by different molecules in their growth and development because they are functionally interconnected and act together to maintain fluid homeostasis in tissues and cell nutrition.
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ECM has a mechanical role in supporting and maintaining tissue architecture but can also be described as a dynamic meshwork actively regulating critical cellular functions such as migration, survival, proliferation, and differentiation. 73 However, less attention has been paid to the role of insoluble ECM molecules in controlling lymphangiogenesis. In an in vitro experiment, T1␣/podoplanin-overexpressing murine hemangioendothelioma-derived cell clones showed a significantly increased ability to form tube-like structures after plating on to Matrigel. 65 In order to analyze the properties of human LECs, dermal microvascular endothelial cells were transfected with a retrovirus containing the coding region of telomerase reverse transcriptase. 74 During invasion and tube formation, however, endothelial cells degrade their basement membrane, and proliferate and migrate into the surrounding collagen-rich matrix. This complex process requires the coordinated activities of many different molecules, including VEGFRs, integrins, and matrixdegrading proteinases. During lymphangiogenesis, the endothelial cells need to interact with matrices composed of changing molecular components. To accomplish this, endothelial cells use different sets of matrix-recognizing receptor molecules, such as integrins, 75, 76 that mediate signals from specific ECM components. For example, endothelial cells upregulate expression of ␣V␤1 that binds to several matrix molecules within the interstitial matrix. 5 Moreover, an important role of keratinocytes and fibroblasts, which constitutively secrete VEGF in vitro, 77 should not be neglected in the regulation of lymphangiogenesis in the skin homeostasis and disease.
Temporal and spatial regulation of ECM remodeling is not only a critical event in the formation and stability of newly formed lymphatic networks but is also involved in lymph node metastasis of tumors. Far beyond the knowledge of lymphangiogenesis, the significance of endothelial cell-matrix interactions has been supported by several ongoing clinical trials that analyze the effects of drugs blocking this interaction on angiogenesis-dependent growth of human tumors. 56 Recent experimental evidence on the important influence of lymphangiogenetic growth factors on intralymphatic cancer growth and metastasis raises hopes that these factors could serve as an additional target for possible lymphatic-associated tumor therapy. 78 The pertinent question actually is how newly formed lymphatics interplay with ECM microenvironment. One possible explanation is that organ-specific structure-functional property of the LECs gauges their response to survival and proliferative factors. Antilymphangiogenic factors might block endothelial cell-receptor interactions, inhibit the activity of lymphangiogenic factors, and interfere with ECM remodeling. Obviously, the identification of the specific mechanisms regulating LEC-ECM interactions during embryonic and pathological lymphatic growth may lead to novel therapeutic applications for diseases characterized by excessive or insufficient lymphangiogenesis. The following sections will be given in more details to gain a better understanding of the LEC-ECM interaction.
HYALURONAN AND LYMPHATICS
The recent progress in lymphatic biology greatly promotes the understanding of molecular players involved in the uptake and degradation of dissolved macromolecules and lymphangiogenesis. Hyaluronan, a high-molecular weight and cell-surface glycosaminoglycan, is one of the major components of the ECM and plays an important role in maintaining tissue integrity, as well as in facilitating the adhesion, migration, and differentiation of cells during inflammation, wound repair, and embryonic development. 55, 79, 80 Unlike most ECM components in the tissues, however, hyaluronan undergoes rapid metabolic turnover, with a halflife of approximately 24 hours. 79 Tissue hyaluronan is released from the ECM, degraded within distant lymph nodes via draining afferent lymph, and removed through efferent lymphatics for terminal hydrolysis within the liver sinusoids. 55, 81, 82 The presence of hyaluronan in lymph and its circulation through the lymphatics is interesting in view of the role of this glycosaminoglycan as a substratum for leukocyte and tumor cell trafficking in perivascular tissues, 83 particularly in pathological states of lymphangiodysplasia or lymph damage. 84 With implant of a biocompatible device capable of guiding lymphatic proliferation in patients, micropatterned surfaces of hyaluronan proved to orient the LEC growth adequately, allowing the regeneration in the desired direction. 85 Hyaluronan in blood and lymph at very low levels (520 ng/ml) rise after increased flux in infection, injury, or neoplasia, or when blockage of the lymphatic vasculature prevents transit of hyaluronan to the lymph nodes during lymphedema. 55, 86 Hyaluronan promotes tumor cell adhesion to laminin and may thereby facilitate invasion of the basement membrane and metastasis in colon carcinoma. 87 High tumoral cytosolic hyaluronan level is suggested to be associated with lesions of unfavorable outcome in gastric cancer patients, 88, 89 involving in the growth and progression of malignant tumors. Inhibition of hyaluronan synthases by transfection with antisense cDNA or removal of hyaluronan by digestion with hyaluronidase would impair adhesion and prevent tumor metastasis, as well as avoid inflammatory insults.
LYVE-1, the lymphatic vascular endothelial hyaluronan receptor-1, has been widely applied in the study of embryonic and pathological lymphangiogenesis. The lymphatics, which also transport CD44ϩve leukocytes, express their own hyaluronan receptor, the distinct, but related molecule. 20, 90 Being a member of the Link protein family whose only other major hyaluronan receptor is directly involved in leukocyte migration and tumor metastasis, LYVE-1, expressed on both the luminal and abluminal surfaces of the LECs, might be involved in either blocking or facilitating cell adhesion, entry, or migration in lymphatics and trafficking of cells within lymph nodes. 55 It is clearly possible that LYVE-1 functions primarily as an hyaluronan transporter, although such transport does not appear to be required in lymphatics due to their free permeability nature to macromolecules. The hyaluronan-dependent transport may be critical in lymph nodes, and in liver or spleen sinusoids, where active uptake and hyaluronan degradation occur. Interestingly, in the thymus of nonobese diabetic mice, the most remarkable biological feature is occurrence of LYVE-1-positive lymphatic compartments (Fig. 2) , which are packed with CD4-and CD8-positive T lymphocytes. These LYVE-1-expressing lymphatics increase in number and size, and extend from the corticomedullary boundary into the medulla with age (unpublished data). In the autoimmune disorder, nevertheless, the alteration may assess a thymic dysfunction, which ultimately leads to abnormal autoreactive regulatory or effector T cells. Recent studies in vitro indicated that a chimeric form of cartilage oligomeric matrix protein-Ang-1, promotes LYVE-1-positive lymphatic formation in mouse cornea, and stimulates colony formation of CD45 Ϫ CD31 ϩ CD34 Ϫ/low LYVE-1 ϩ LECs. 91 However, the cell analysis in LYVE-1-defined microenvironments and their interaction with chemokines, cytokines, and other factors, has not been fully determined as yet, especially whether it possesses potent and selective attractant activity for circulating naive lymphocytes. 55 
INTEGRINS, ENDOSTATIN, REELIN, IL-7, MMPS, AND LYMPHATICS
Endothelial cell-ECM interactions may provide distinct spatial and molecular signals for proliferation, survival, migration, and differentiation of endothelial cells during angiogenesis and lymphangiogenesis. Integrin-mediated cell-matrix interactions are critical for a diversity of cellular processes (e.g., lack of contact with the matrix may induce apoptosis). 92 Integrins are heterodimeric transmembrane proteins composed 18 known ␣ and 8 ␤ subunits. They are expressed on endothelial cells and mediate adhesion to a variety of ECM proteins including vitronectin, fibronectin, laminin, collagen, fibrinogen, and von Willebrand factor, 93 among which ␣9 has been previously shown to be involved in lymphatic formation. 94 In lymphangiogenesis, the engagement of integrins is essential for new lymphatic development in a selective manner, but involvement of specific integrins and growth factor receptors seems important for the process. The modifications in the ECM compartment or in the cellular integrin profile during the perinatal period, might affect both the normal differentiation of tissue cells as well as the migration, retention, and differentiation of monocytes and macrophages in the developing tissues. 95 Recent progress in endothelial cell biology has paved the way for studying the importance of integrins by using transgenic or gene-knockout animals. In VEGF-A transgenic mice, the significantly enlarged lymphatics were increased in numbers within the granulation tissue. VEGF-A potently upregulated the expression of the ␣1 and ␣2 integrins in cultured human LECs, promoting their capacity to form cords and haptotactic migration. Interestingly, blockade of both these integrins in vitro inhibited VEGF-A-induced cord formation and LEC migration toward collagen but not toward fibronectin. 71 Incubation of LECs with an integrin␣9-specific blocking antibody inhibited heptocyte growth factor-induced migration. 75 Mice homozygous for a null mutation of the integrin␣9 subunit die 6-12 days after birth from bilateral chylothoraces, suggesting an underlying defect in lymphatic development. When embryonic fibroblasts of mouse and tumor cells of human were transfected to express ␣9␤1, these cells adhered and/or migrated on VEGF-C/-D in a concentration-dependent fashion, showing that VEGF-C/-D are ligands for the integrin␣9␤1. 76 The study on the interaction between␣9␤1 and VEGF-C and/or -D may be forceful to explain the abnormal lymphatic phenotype of the␣9 knock-out mice.
Both integrin-mediated and receptor tyrosine kinase-mediated signaling pathways are involved in endothelial cell growth and survival. 96 The process for angiogenesis indicated that endothelial cell-ECM interactions directly regulate endothelial behavior either through receptor-mediated signaling or by modulating the cellular response to growth factors. 97 Integrins may thus transmit intracellular signals and activate signaling proteins, including growth factor receptor tyrosine kinases. In lymphangiogenesis, recent study showed a novel connection between integrin-mediated adhesion and critical endothelial cell functions via VEGFR-3, which with its ligands are believed to be powerful lymphangiogenic factors. The integrin ␣5␤1 subunit may activate both VEGFR-3 and its downstream PI3 kinase/Akt signaling pathway, which is essential for fibronectin-mediated LEC survival and proliferation. The fibronectin, vice versa, the ligand for integrin ␣5␤1, was found to transactivate VEGFR-3 and significantly enhanced the phosphorylation of VEGFR-3 induced by VEGF-C156S as compared to vitronectin. 5 Furthermore, the interaction of ␣5␤1 or ␣6␤1 on tumor cells, which appropriate levels of integrins, with fibronectin in several tissues is involved in lymph node metastases. [98] [99] [100] A good example of the interplay between the different classes of molecules participating in ECM recognition and remodeling is the regulation of the synthesis and function of the endogenous protein endostatin. The polypeptide is distinguished by strong antiangiogenic activity in vivo restricting the growth of solid tumors and metastasis, and the migration of endothelial cells. Endostatin is C-terminal fragment of the noncollagenous domains of collagen XVIII, a component of the vascular basement membranes. 101 The cellular signaling induced by endostatin is characterized by a large number of individual genetic signals, which are highly coordinated and interdependent. 102 Endostatin may exert its function by binding to endothelial cell surface integrins, such as ␣V␤3 and ␣5␤1, 103 or by blocking activation or catalytic activity of endothelial matrix metalloproteinases (MMPs), such as MMP-2 and MMP-14. 104 Recently, the experiment in vitro indicated that endostatin is able to inhibit the migration and proliferation of LECs, and the effect on these cells is dose-dependent. 105 Reelin, a glycoprotein secreted by Cajal-Retzius cells, is a serine protease of the extracellular matrix, which rapidly degrades fibronectin and laminin. 106 The immunohistochemical staining in human and rat fetus demonstrated the expression of reelin on LECs, but not on BECs, 107 indicating it may contribute to the special phenotype both during lymphangiogenesis and in mature lymphatics. Kaposi's sarcoma-associated herpesvirus infection of human dermal microvascular endothelial cells induces significant upregulation of the lymphatic lineage-specific gene, reelin, 108 indicating the origin of Kaposi's sarcoma from LECs. IL-7 specifically increases the expression of lymphatic markers, LYVE-1, podoplanin, and Prox-1 in endothelial cells, and induces the lymphangiogenic properties of breast cancer cells in vivo, probably by upregulation of VEGF-D. 109 Degradation of the ECM components by MMPs will greatly influence the LEC-ECM interaction. MMP-9, a member of the family of MMP genes, encodes zinc-dependent enzymes that break down ECM through the degradation of type IV collagen. 110 The prognostic value of MMP-9 expression by tumor metastasis has been reported in relation to a variety of cancers. 111, 112 In an in vitro experiment, the activity of both MMP-2 and MMP-9 produced by cancer cells was expressed by murine LECs, but strongly inhibited by MMI270, the MMP inhibitory compound, 78 suggesting that MMI270 might be involved in tumor metastasis on the basis of its downregulation in the lymphangiogenesis-related properties of LECs and the invasive properties of cancer cells. Attention should be directed to the fact that MMPs act as mediators of lymphangiogenesis and tumor metastasis, although there is a great possibility that different MMPs serve individual and specific roles during the different stages of the capillary or/and metastatic formation.
Indeed, a diversity of cell types and various local ECM environments exist in different tissues, therefore, a unique intracellular signaling pathway relating to lymphangiogenic phenotypes, and an intrinsic relationship between the ECM protein, molecular regulator on LECs and tumor biology, need to be urgently clarified.
MORPHOGENETIC RESPONSES OF LECS TO INTERSTITIAL FLOW-BIOPHYSICAL ENVIRONMENT
The extent of similarity between the processes of lymphangiogenesis and angiogenesis is poorly understood, although they share many molecular regulators and serve complementary functions. In contrast to the blood circulation, the primary function of the lymphatic system is to maintain interstitial fluid balance and provide lymph clearance of interstitial fluid and macromolecules, thereby sustaining osmotic and hydrostatic gradients from blood capillaries through the interstitium and stimulating convection for interstitial protein transport. The management and control of tissue fluid balance depends on the highly regulated orchestration of various interstitial factors. In particular, lymphatic function, biology and development (lymphangiogenesis), and the ECM all contribute to interstitial fluid balance. It is plausible to suggest that an important physiological regulating factor of lymphangiogenesis may be the maintenance of interstitial fluid balance and protein convection and, vice versa, that interstitial fluid flow may play a role in lymphangiogenesis. 113 It is well accepted that mechanical forces such as fluid shear and matrix strain take part in regulating blood capillary morphogenesis and endothelial cell morphology. 114, 115 Interstitial flow, as a powerful morphoregulatory stimulant, is a functionally critical component of the circulation, in which high shearing flows are known to induce endothelial cell remodeling, whereas very low interstitial flow rates trigger endothelial cell morphogenesis in three-dimensional collagen gel cultures. The latter are usually involved in microvascular organization and stabilization in vitro, promoting the formation of large vacuoles with geodesic actin networks and long dendritic extensions in LECs, and greatly enhance networking and multicellular tubulogenesis, particularly in BECs. 116 In a regenerating region of skin, the interstitial flow was observed to drive the formation of fluid channels along which LECs migrate, proliferate, and finally reorganize into a functional lymphatic network. Moreover, increased MMP activity in the model of lymphatic development could lead to preferential cell migration in the direction of flow. 117 The improved lymphatic function persisted in the VEGF-C treated mice, despite the fact that adenoviral VEGF-C gene expression was downregulated and part of the generated lymphatics regressed during the follow-up period. 118 The lymphatics that become functional remain stable in the tissue even without continuous growth factor stimulation. It is due to that interstitial flow is present to some degree in all tissues and, importantly, constitutes the biophysical environment in tissues undergoing lymphatic development.
CONCLUSIONS
The lymphatic research in recent years has revolutionized the field of cell and molecule biology, with the accelerating emerging awareness of the complex interplay between LECs and ECM. Critical and important events regarding lymphangiogenesis are strongly affected by changing ECM microenvironment and are supposed to play a key role in lymphatic-associated disorders. The new insights into lymphangiogenesis and ECM composition and organization will lead to a better understanding of the mechanisms of unique lymphatic-specific growth factors, cytokines, and chemokines.
